APA (7th ed.) Citation

Liang, H., Li, T., Fang, X., Xing, Z., Zhang, S., Shi, L., . . . Yang, Q. (2021). IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer. Cancer letters, 522, 32-43. https://doi.org/10.1016/j.canlet.2021.09.012

Chicago Style (17th ed.) Citation

Liang, Heng, et al. "IDO1/TDO Dual Inhibitor RY103 Targets Kyn-AhR Pathway and Exhibits Preclinical Efficacy on Pancreatic Cancer." Cancer Letters 522 (2021): 32-43. https://doi.org/10.1016/j.canlet.2021.09.012.

MLA (9th ed.) Citation

Liang, Heng, et al. "IDO1/TDO Dual Inhibitor RY103 Targets Kyn-AhR Pathway and Exhibits Preclinical Efficacy on Pancreatic Cancer." Cancer Letters, vol. 522, 2021, pp. 32-43, https://doi.org/10.1016/j.canlet.2021.09.012.